83889-95-6

Basic information

• Product Name: 2-(1-hydroxyethyl)naphtho[2,3-b]furan-4,9-dione
• Synonyms: 2-(1-Hydroxyethyl)naphtho(2,3-b)furan-4,9-dione; Naphtho(2,3-b)furan-4,9-dione, 2-(1-hydroxyethyl)-; naphtho[2,3-b]furan-4,9-dione, 2-(1-hydroxyethyl)-
• CAS NO: 83889-95-6
• Molecular Formula: C₁₄H₁₀O₄
• Molecular Weight: 242.2268
• Mol File: 83889-95-6.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 428.5°C at 760 mmHg
• Flash Point: 213°C
• Density: 1.4g/cm³
• Vapor Pressure: 4.18E-08mmHg at 25°C
• Refractive Index: 1.636
• CAS DataBase Reference: 2-(1-hydroxyethyl)naphtho[2,3-b]furan-4,9-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-hydroxyethyl)naphtho[2,3-b]furan-4,9-dione(83889-95-6)
• EPA Substance Registry System: 2-(1-hydroxyethyl)naphtho[2,3-b]furan-4,9-dione(83889-95-6)

Safety Data

• Hazardous Substances Data: 83889-95-6(Hazardous Substances Data)

Usage

Furan-2,3-dione derivative

A chemical structure based on a furan ring (a five-membered ring with one oxygen atom and four carbon atoms) with two carbonyl groups (C=O) at the 2nd and 3rd positions.

Naphtho[2,3-b]furan ring system

A fused ring structure consisting of a naphthalene (a ten-carbon aromatic ring system) and a furan ring sharing two adjacent carbon atoms at positions 2 and 3.

Hydroxyethyl group

A functional group containing an oxygen atom bonded to a carbon atom, which is in turn bonded to two hydrogen atoms and an ethyl group (-CH2-CH3).

Attached at the 2-position

The hydroxyethyl group is attached to the second carbon atom of the naphtho[2,3-b]furan ring system.

Potential biological activities

The compound's structural features may lead to interactions with biological systems, making it a candidate for further study in the field of medicinal chemistry.

Applications in medicinal chemistry

Due to its potential biological activities, the compound may be useful in the development of new drugs or therapies.

Interesting for further study

The compound's unique structure and potential applications make it a valuable subject for research in various scientific and industrial fields.

Upstream product

• 3126-04-3 1-(tributylstannyl)-3-(tributylstanyloxy)-1-butyne 
• 29366-43-6 2-hydroxy-3-(1-n-butenyl)-1,4-naphthoquinone 
• 18633-71-1 2-ethyl-4H,9H-naphtho[2,3-b]furan-4,9-dione 
• 83-72-7 2-hydroxynaphtho-1,4-quinone 
• 1203-39-0 3-bromolawsone 
• 130-15-4 [1,4]naphthoquinone 
• 1785-67-7 1,2,4-triacetyloxynaphthalene 
• 117560-06-2 3-phenyliodonio-1,2,4-trioxo-1,2,3,4-tetrahydronaphthalenide 
• 2028-63-9 but-3-yn-2-ol 
• 2348-79-0 2-dimethylamino-1,4-naphthoquinone 
• 2065-37-4 2-bromo-1,4-naphthoquinone 
• 91394-68-2 2-bromo-3-(dimethylamino)naphthalene-1,4-dione 
• 92487-46-2 2-(2-furylmethyl)benzoic acid 
• 57901-54-9 2-(2-furoyl)benzoic acid 

Downstream Products

• 83280-65-3 2-acetylnaphtho[2,3-b]furan-4,9-quinone 

Relevant articles and documents

Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer

Increasing evidence indicates that the cancer stem cell (CSC) subpopulation contributes to the therapeutic resistance and metastasis of tumors, leading to patient recurrence and death. Herein, we designed and synthesized several compounds by conjugating lapatinib derivatives with different CSC inhibitors to treat with lapatinib-induced MDA-MB-231 drug-resistant cells. In vitro biological studies indicated that 3a showed strong cytotoxicity and EGFR enzyme inhibitory activity and effectively reversed lapatinib-mediated resistance of MDA-MB-231 cells via inhibiting triple-negative breast cancer (TNBC) cell stemness and the AKT/ERK signaling pathway. In addition, 3a was capable of strongly suppressing the invasion and migration of TNBC cells by inhibiting the Wnt/β-catenin signaling pathway and MMP-2 and MMP-9 protein expression. In vivo tumorigenicity tests showed that 3a could inhibit the occurrence of TNBC by inhibiting BCSCs, proving 3a is a potential EGFR and CSC dual inhibitor for TNBC treatment.

Novel small molecule compound, preparation method and application thereof in preparation of mycobacterium drugs for resisting drug-resistant mycobacterium tuberculosis and like

The invention discloses a novel small molecule compound and a preparation method and application thereof in preparation of mycobacterium drugs for resisting drug-resistant mycobacterium tuberculosis and like. The novel mycobacterium-resistant small molecule has a structural general formula (I), and the small molecule compound disclosed by the invention has a relatively good inhibition effect on mycobacteria. The antibacterial activity of mycobacterium smegmatis, mycobacterium tuberculosis H37Rv, H37Ra and drug-resistant mycobacterium tuberculosis are determined, and results show that the smallmolecule compound has good antibacterial activity on mycobacterium smegmatis, mycobacterium tuberculosis H37Rv, H37Ra and drug-resistant mycobacterium tuberculosis, and has an application prospect inpreparation of mycobacterium tuberculosis-resistant drugs.

Design, synthesis and activity of BBI608 derivatives targeting on stem cells

STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells. BBI608, a small molecule identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types. In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivatives were designed and synthesized here. Most of these compounds were more potent than BBI608 on HepG2 cells, compound LD-8 had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC50 = 11.2 μM), but had considerable activity on normal liver cells L-02. Compounds LD-17 (IC50 = 3.5 μM) and LD-19 (IC50 = 2.9 μM) were found to possess significant inhibitory activities and good selectivity. The results showed that compound LD-19 was worthy to investigate further as a lead compound according to its potent inhibitory activity, ideal ClogP value and better water solubility.